New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...
GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market. Top-line results ...
GlaxoSmithKline and partner Innoviva are seeking an expansion to the US label of their Trelegy Ellipta lung drug. Trelegy Ellipta got its first US approval in September as a daily long-term ...
GlaxoSmithKline has seized the initiative with its three-drug COPD inhaler Trelegy Ellipta despite some new competition from AstraZeneca. To cement its lead, GSK is looking for a first-of-its-kind ...
With generics attacking Advair, GlaxoSmithKline has talked up prospects for 3-in-1 respiratory med Trelegy. Now, the company has data in hand that could help it move into the asthma arena—though it's ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using TRELEGY ELLIPTA? TRELEGY ELLIPTA contains the active ...
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use ...
LONDON & BURLINGAME, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results